NEUMOLOGÍA PEDIÁTRICA

Neumol Pediatr 2020; 15 (4): 429 - 483 C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl 478 Consenso chileno para la atención integral de niños y adultos con fibrosis quística REFERENCIAS 1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992–2001. 2. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361(9358):681–9. 3. Paranjape SM, Mogayzel PJ. Cystic fibrosis. Pediatr Rev. 2014;35(5):194–205. 4. Boza L, Lobo G, Henríquez M, Valdebenito S, Espinoza X, Navarro S, et al. Resultado programa piloto. Pesquisa neonatal de fibrosis quistica en la Región Metropolotana y V Región. Período 2015 – 2017. Neumol Pediátrica. 2017;12:195. 5. Lay-Son G, Puga A, Astudillo P, Repetto GM. Cystic fi- brosis in Chilean patients: Analysis of 36 common CFTR gene mutations. J Cyst Fibros. 2011;10(1):66–70. 6. Cerda L J, Valdivia C G, Guiraldes C E, Sánchez D I. Mor- talidad por fibrosis quística en Chile (1997-2003). Rev Med Chil. 2008;136(2):157–62. 7. Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153–78. 8. Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017;181:S4-S15.e1. 9. Sosnay PR, White TB, Farrell PM, Ren CL, Derichs N, Howenstine MS, et al. Diagnosis of Cystic Fibrosis in Nonscreened Populations. J Pediatr. 2017;181:S52-S57. e2. 10. Eng W, LeGrys VA, Schechter MS, Laughon MM, Barker PM. Sweat-testing in preterm and full-term infants less than 6 weeks of age. Pediatr Pulmonol. 2005;40(1):64– 7. 11. Legrys VA, Briscoe D, Mccolley SA. Sweat Testing: Speci- men collection and quantitative chloride analysis. 4th ed. Wayne PC and LSI, editor. Vol. 39. 2019. 12. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, et al. European cystic fibrosis society standards of care: Best practice guidelines. J Cyst Fibros. 2014;13(S1). 13. Fielbaum OD. Test del sudor, técnica y errores. Neumol Pediatr. 2016;11(1):19–22. 14. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibro- sis: A consensus statement. J Pediatr. 1998;132(4):589– 95. 15. Barben J, Rueegg CS, Jurca M, Spalinger J, Kuehni CE, Barazzone C, et al. Measurement of fecal elastase impro- ves performance of newborn screening for cystic fibrosis. J Cyst Fibros. 2016;15(3):313–7. 16. Vanga RR, Tansel A, Sidiq S, El-Serag HB, Othman MO. Diagnostic performance of measurement of fecal elas- tase-1 in detection of exocrine pancreatic insufficiency: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(8):1220-1228.e4. 17. Daftary A, Acton J, Heubi J, Amin R. Fecal elastase-1: Utility in pancreatic function in cystic fibrosis. J Cyst Fi- bros. 2006;5(2):71–6. 18. Coffey MJ, Whitaker V, Gentin N, Junek R, Shalhoub C, Nightingale S, et al. Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the New- born Screening Era. J Pediatr. 2017;181:137-145.e1. 19. Boza ML. Fibrosis quistica y tamizage neonatal. Neumol Pediatr. 2016;11(1):10–4. 20. Sarles J, Giorgi R, Berthézène P, Munck A, Cheillan D, Dagorn JC, et al. Neonatal screening for cystic fibrosis: Comparing the performances of IRT/DNA and IRT/PAP. J Cyst Fibros. 2014;13(4):384–90. 21. Sermet-Gaudelus I, Mayell SJ, Southern KW. Guidelines on the early management of infants diagnosed with cys- tic fibrosis following newborn screening. J Cyst Fibros. 2010;9(5):323–9. 22. Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A, Farrell M, et al. European best practice guide- lines for cystic fibrosis neonatal screening. J Cyst Fibros. 2009;8(3):153–73. 23. Sly PD, Brennan S, Gangell C, De Klerk N, Murray C, Mott L, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med. 2009;180(2):146–52. 24. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Cas- tellani C, Cutting GR, et al. Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cys- tic Fibrosis Foundation Consensus Report. J Pediatr. 2008;153(2). 25. PharmGKB [Internet]. [citado 28 de agosto de 2020]. Disponible en: https://www.pharmgkb.org/ 26. Welcome to CFTR2 | CFTR2 [Internet]. [citado 28 de agosto de 2020]. Disponible en: https://cftr2.org/ 27. den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Green- blatt MS, Mcgowan-Jordan J, et al. HGVS Recommen- dations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016;37(6):564–9. 28. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. 29. Ren CL, Borowitz DS, Gonska T, Howenstine MS, Levy H, Massie J, et al. Cystic Fibrosis Transmembrane Conduc- tance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis. J Pe- diatr. 2017;181:S45-S51.e1. 30. Munck A, Mayell SJ, Winters V, Shawcross A, Derichs N, Parad R, et al. Cystic Fibrosis Screen Positive, Inconclu- sive Diagnosis (CFSPID): A new designation and manage- ment recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros. 2015;14(6):706–13. 31. Southern KW, Barben J, Gartner S, Munck A, Castellani C, Mayell SJ, et al. Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition. J Cyst Fibros. 2019;18(6):778–80. 32. Clinical guidelines: Care of children with cystic fibrosis, 2020 | Royal Brompton & Harefield NHS Foundation Trust [Internet]. [citado 4 de septiembre de 2020]. Disponible en: https://www.rbht.nhs.uk/childrencf